Empavic L (Empagliflozin + Linagliptin)

Indication

Used alongside diet and exercise to improve blood sugar control in adults with Type 2 Diabetes Mellitus.

How It Works

• Linagliptin (DPP-4 Inhibitor): Increases active incretin levels (GLP-1 and GIP) to boost glucose-dependent insulin release and reduce glucagon production.

• Empagliflozin (SGLT2 Inhibitor): Blocks kidney glucose reabsorption, prompting excess glucose to be excreted in urine.

Dosage & Administration

• Starting Dose: Empagliflozin 10 mg / Linagliptin 5 mg once daily in the morning (with or without food).

• Maximum Dose: Empagliflozin 25 mg / Linagliptin 5 mg once daily.

• Kidney Function: Assess renal function before starting. Do not use if eGFR falls below 45 mL/min/1.73 m².

Key Precautions & Warnings

• Contraindications: Severe renal impairment, ESRD, dialysis, or known hypersensitivity to either ingredient.

• Pregnancy: Not recommended, particularly during the 2nd and 3rd trimesters.

• Serious Adverse Risks: Pancreatitis, diabetic ketoacidosis (DKA), Fournier’s gangrene, severe UTIs (urosepsis), volume depletion/hypotension, and heart failure.

• Other Side Effects: Genital mycotic infections, hypoglycemia (if combined with insulin), joint pain, and bullous pemphigoid.

Drug Interactions & Diagnostics

• Diuretics: Increases dehydration and low blood pressure risk.

• Insulin/Secretagogues: Heightens hypoglycemia risk.

• Rifampin (P-gp/CYP3A4 Inducers): Can reduce Linagliptin effectiveness.

• Lab Interference: Results in positive urine glucose tests and unreliable 1,5-AG assay measurements.

Storage

Store below 30°C in a dry, dark place, out of reach of children.

Note: Always take this medication under the supervision of a registered physician.